Skip to main content

Table 1 Patient demographics

From: Clinical course and significance of nontuberculous mycobacteria and its subtypes in cystic fibrosis

  Patients with Slow-growing NTM #1 (N = 17) Patients with Rapidly Growing NTM #2 (N = 8) NTM-negative Patients #3 (N = 26) P-values
  N N (%) or median (range) N N (%) or median (range) N N (%) or median (range) Overall 1 vs 2 1 vs 3 2 vs 3
Age at first positive NTM culture, years 17 16.4 (6.4–41.6) 8 16.4 (3.1–21.5)   0.44a 0.44a   
Gender 17   8   26   0.93 0.99 0.75 0.99
 Male   9 (53)   5 (63)   16 (62)     
 Female   8 (47)   3 (37)   10 (38)     
Age at CF diagnosis in months 11 1.2 (0.1–2.8) 5 4.5 (1.5–84.3) 22 2.4 (< 1–164.4) 0.046 0.013 0.053 0.52
Race 15   8   26   0.37 0.35 0.29 0.99
 Caucasian   15 (100)   7 (88)   23 (88)     
 Black/Hispanic    1 (12)   3 (12)     
CF diagnosis method b 12   5   24      
 Newborn screening   8 (67)   1 (20)   10 (42) 0.24 0.18 0.75 0.23
Concomitant symptoms
 Meconium   3 (25)    5 (21) 0.51 0.53 0.99 0.31
 Chronic cough   1 (8)    0.49 0.99 0.40
 Recurrent respiratory infection   2 (17)   4 (80)   10 (42) 0.08 0.06 0.09 0.69
 Failure to thrive   3 (25)   4 (80)   8 (33) 0.25 0.16 0.48 0.41
 Frequent greasy or bulky stools   1 (8)    0.49 0.99 0.40
 Nasal polyps     1 (4) 0.92 0.99 0.99
 Other   1 (8)   2 (40)   4 (17) 0.41 0.23 0.63 0.61
p.F508del mutation status 17   8   26   0.44 0.46 0.25 0.84
 2 copies   10 (59)   4 (50)   17 (65)     
 1 copy   7 (41)   3 (38)   6 (23)     
 0 copies    1 (12)   3 (12)     
Sweat-chloride level at diagnosis, mmol/L 13 101 (74–121) 5 105 (100–142) 22 109 (90–137) 0.026c 0.095 0.009 0.99
Pancreatic insufficiency 17   8   26   0.92 0.99 0.99
 No     1 (4)     
 Yes   17 (100)   8 (100)   25 (96)     
Diabetes diagnosis 17   8   26   0.67 0.99 0.67 0.57
 No   14 (82)   6 (75)   23 (88)     
 Yes   3 (18)   2 (25)   3 (12)     
FEV1 percent predicted
 Before NTM acquisition 17 92 (53–115) 7 84 (71–102) 0.80 0.80
 After NTM acquisition 17 91 (36–110) 8 80 (48–91) 0.23 0.23
FEF25–75% predicted
 Before NTM acquisition 17 79 (24–124) 7 64 (42–123) 0.80 0.80
 After NTM acquisition 17 68 (13–110) 8 51 (24–103) 0.59 0.59
Organism type 17   8    ≤0.001 ≤0.001
 MAC   15 (88)       
M. fortuitum    2 (25)      
M. abscessus    6 (75)      
M. gordonae   2 (12)       
Number of positive NTM cultures 17 1 (1–3) 8 2.5 (1–7) 0.18 0.18
  1. aSignificant difference between patients infected with rapidly growing bacteria and NTM-negative patients (P = 0.013)
  2. bMore than one method of diagnosis may have been used
  3. cSignificant difference between patients infected with slow-growing bacteria and NTM-negative patients (P = 0.009)
\